Get a head STaRT in the fight against brain tumors

Tough on the tumor. Easier on you and your caregivers.

A radiation treatment specifically designed for use inside the brain, GammaTile Therapy gives patients new hope in the fight against brain tumors. It can eliminate the need for traditional repeat radiation treatments and associated hospital or clinic visits, so patients can focus on what matters most—healing.

Is GammaTile Therapy right for you?

Find out by answering a few simple questions.

Watch this animation, which was designed for patients and caregivers to show how GammaTile Therapy works.

How it works

Your neurosurgeon places GammaTile(s) precisely where and when treatment will help the most—at the tumor site immediately after tumor removal.

Radiation is focused right where it is needed—where the tumor is most likely to recur.

GammaTile is designed to protect healthy tissue, minimizing radiation side effects, including hair loss.[1]

Radiation therapy occurs as you go about your daily life.

The Benefits Are Clear

Improved Local Tumor Control

For patients with recurrent meningiomas and recurrent brain metastases, the use of GammaTile Therapy demonstrated a significant delay in treatment site recurrence compared to their previous treatments.[2,3]

Improved Survival

GammaTile Therapy demonstrates a potential for improved overall survival when comparing the effectiveness of surgery plus GammaTile Therapy to other treatment modalities across different clinical studies in patients with recurrent glioblastoma (GBM).[4,5]

Get a head STaRT in the fight against brain tumors.

Find a GammaTile Therapy Center near you.

GammaTile Therapy: Clinical Outcomes

Improved local tumor control in patients with recurrent meningiomas and recurrent brain metastases

MENINGIOMA PATIENTS RECURRENCE FREE AT 2 YEARS[3]

BRAIN METASTASES PATIENTS RECURRENCE FREE AT 1 YEAR[4]

Potential to extend overall survival in patients with recurrent glioblastoma (GBM)

RECURRENT GBM PATIENTS MEDIAN OVERALL SURVIVAL[4,5]

Learn about the company that developed GammaTile Therapy.

REFERENCES:

  1. Brachman D, Youssef E, Dardis C, Smith K, Pinnaduwage D, Nakaji P. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.
  2. Rogers L, Nakaji P, Youssef E, et al. Resection and surgically targeted radiation therapy for initial salvage treatment of aggressive meningioma: results from a prospective trial. Presented at: CNS 2020 Virtual Conference; September 30, 2020.
  3. Nakaji P, Smith K, Youssef E, et al. Resection and surgically targeted radiation therapy for the treatment of larger recurrent or newly diagnosed brain metastasis: results from a prospective trial. Cureus. 12(11):1-12.
  4. Brachman D, Nakaji P, Smith K, et al. Resection and Surgically Targeted Radiation Therapy for locally recurrent GBM. J Clin Oncol. 2021;39(15):abstr 2054.4.
  5. Tsien C, Pugh S, Dicker AP, et al. Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and RT plan quality report. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):578.